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Background: Health authorities in numerous countries recommend periconceptional folic acid supplementation to
prevent neural tube defects. The objective of this study was to examine the association of dietary folate intake and
folic acid supplementation during different periods of pregnancy with the risk of spontaneous preterm delivery
(PTD).
Methods: The Norwegian Mother and Child Cohort Study is a population-based prospective cohort study. A total
of 66,014 women with singleton pregnancies resulting in live births in 2002–2009 were included. Folic acid
supplementation was self-reported from 26 weeks before pregnancy until pregnancy week 24. At gestational week
22, the women completed a food frequency questionnaire, which allowed the calculation of their average total
folate intake from foods and supplements for the first 4–5 months of pregnancy. Spontaneous PTD was defined as
the spontaneous onset of delivery between weeks 22+0 and 36+6 (n = 1,755).
Results: The median total folate intake was 313 μg/d (interquartile range IQR 167–558) in the overall population
and 530 μg/d (IQR 355–636) in the supplement users. Eighty-five percent reported any folic acid supplementation
from <8 weeks before to 24 weeks after conception while only 44% initiated folic acid supplementation before
pregnancy. Cox regression analysis showed that the amount of dietary folate intake (hazard ratio HR 1.00; confidence
interval 95% CI 0.61-1.65) and supplemental folate intake (HR 1.00; CI 1.00-1.00) was not significantly associated with the
risk of PTD. The initiation of folic acid supplementation more than 8 weeks before conception was associated with an
increased risk for spontaneous PTD (HR 1.18; CI 1.05-1.32) compared to no folic acid supplementation preconception.
There was no significant association with PTD when supplementation was initiated within 8 weeks preconception
(HR 0.99; CI 0.87-1.13). All analyses were adjusted for maternal characteristics and socioeconomic, health and dietary
variables.
Conclusions: Our findings do not support a protective effect of dietary folate intake or folic acid supplementation on
spontaneous PTD. Preconceptional folic acid supplementation starting more than 8 weeks before conception was
associated with an increased risk of spontaneous PTD. These results require further investigation before discussing an
expansion of folic acid supplementation guidelines.
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Folate is a B-vitamin essential for one-carbon metabol-
ism and takes part in amino acid metabolism as well as
DNA synthesis, repair and methylation [1,2]. Women
are especially susceptible to folate deficiency during
pregnancy, which is a period of rapid fetal growth, organ
differentiation and high rates of cell division [1,3,4].
Since the 1950s, folic acid supplementation has been
known to prevent megaloblastic anemia during preg-
nancy [5]. In the 1990s, large randomized trials demon-
strated that periconceptional folic acid supplementation
can prevent neural tube defects (NTDs) in the newborn
infant [6-8]. Today, national health authorities in many
countries recommend periconceptional folic acid sup-
plementation, and some countries have introduced
mandatory folate fortification of foods [1,3,4,9,10]. In
Norway, folic acid supplementation of 400 μg/d is rec-
ommended from the time of planning a pregnancy to
gestational week 12 [2,11], as is a daily folate intake of
500 μg/d. This is in line with the Nordic Nutrition Rec-
ommendations [2].
Maternal folate status has also been associated with
other adverse pregnancy outcomes such as preeclamp-
sia, malformations such as orofacial clefts, spontaneous
abortion, fetal death, fetal growth restriction and pre-
term delivery (PTD), although these results still remain
inconclusive [1].
PTD, defined by the World Health Organization
(WHO) as birth occurring before 37 weeks of gestation,
is considered a major global health problem and is
strongly associated with neonatal mortality as well as
short- and long-term morbidity [12-14]. Spontaneous
PTD is a common, complex condition with a prevalence
of approximately 7% in the Norwegian population [15].
However, the effect of any single environmental factor
is difficult to measure without large-scale studies [15].
Modern obstetrics are still not able to predict, prevent
or treat PTD [16]. Progesterone substitution, the only
promising intervention identified to date, has been shown
to reduce the chance of spontaneous PTD in high-risk
pregnancies, but such cases account for only a small pro-
portion of all pregnancies [17,18].
In the past decade, some observational studies have
found that folic acid supplementation reduces the risk of
PTD [19-22]. In some studies, this effect has been docu-
mented with an extended folic acid supplementation
scheme or dosage compared with schemes based on
NTD prevention, e.g., preconceptional folic acid supple-
mentation for one year or longer [21] or third-trimester
folic acid supplementation [22]. A study based on the
previous Cochrane review and data of one of the largest
randomized controlled trials (RCT), a recent meta-analysis
of all published RCTs, as well as the recent Cochrane re-
view based on 3 controlled trials could not confirm anyeffect of the maternal folate status on the gestational
length or the risk of spontaneous PTD [23-25]. The
comparability and generalizability of these earlier stud-
ies, which focused on the association of folate status
and folic acid supplementation with pregnancy out-
come, is limited because folic acid supplementation was
assessed without considering other folate sources, the
study populations had different levels of dietary folate
intake, inadequate sample sizes, limited adjustment for
important confounders, and/or retrospective study de-
signs with folate data collection only after delivery [1,4].
Although PTD is a heterogeneous pregnancy outcome
with different etiologies (early vs. late or iatrogenic vs.
spontaneous), previous studies have mostly treated PTD as
one entity, obscuring the differences in risk among PTD
subtypes [26,27].
The Norwegian Mother and Child Cohort Study (MoBa)
can meet a number of these challenges in study design, a
requirement for addressing the inconsistencies in the field.
MoBa includes more than 106,000 pregnancies, enabling
the investigation of common complex pregnancy out-
comes such as PTD. A detailed prospective assessment of
folic acid supplementation starting from 6 months before
conception throughout pregnancy, data regarding dietary
folate intake and comprehensive information about life-
style habits, health and socioeconomic status provide a
unique opportunity to study the association between folate
intake and PTD. For example, the effect of folic acid sup-
plementation can be compared between women with low
and high dietary folate intakes. By taking into account the
amount of dietary folate and folic acid supplementation
during different periods of pregnancy, it might be possible
to define the folic acid supplementation scheme most
likely to affect PTD risk.
The aim of this study was to examine the association
of maternal folate intake from both supplemental and
dietary sources with the risk of spontaneous PTD, with
sub-analyses of early and late spontaneous PTD. The as-
sociation of folic acid supplementation with PTD was
studied in a stratified sample of women with low and
high dietary folate intakes (</≥170 μg/d).
Methods
Study population
The dataset is part of the MoBa cohort, initiated by and
maintained at the Norwegian Institute of Public Health
[15]. In brief, MoBa is a nation-wide pregnancy cohort
that has included more than 106,000 pregnancies in the
years from 1999 to 2009. The women were recruited
through a postal invitation in connection with a routine
ultrasound examination offered to all pregnant women
in Norway approximately 17 weeks of gestation. Overall,
38.5% of the invited women participated. They were
asked to fill in questionnaires focused on overall health
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15–17 (Q1) and 30 (Q3). At week 22, they completed a
food frequency questionnaire (FFQ). All questionnaires
are available from the homepage of the Norwegian Insti-
tute of Public Health [28]. The present study used data
from version 6 of the quality-assured data files made
available for research in 2011. The MoBa database is
linked to pregnancy and birth records from the Medical
Birth Registry of Norway (MBRN) [29]. Informed written
consent was obtained from each participant. The Regional
Committee for Medical Research and the Norwegian Data
Inspectorate approved the study.
Of 106,707 pregnancies included in the MoBa version
6, 103,921 pregnancies resulted in live-born singletons.
Complete data for all 3 questionnaires including infor-
mation about folate intake were available for 81,329
pregnancies. Women reporting improbable energy in-
takes of <4.5 MJ or >20 MJ were excluded [30], leaving
80,056 pregnancies. After exclusion of women with pre-
pregnancy diabetes mellitus, chronic hypertension, chronic
kidney disease, epilepsia, rheumatoid arthritis and those
that underwent in-vitro fertilization, 76,298 pregnancies
were included in the study. Pregnancies with a gestational
length of <22+0 or >42+6 weeks were excluded from fur-
ther analysis, leaving 75,873 remaining. If a woman par-
ticipated for more than one pregnancy, only her first
pregnancy enrolled was included, leaving 66,014 preg-
nancies for analyses.
Outcome
The gestational age in days was determined with a
second-trimester ultrasound in 98.4% of the pregnancies
and was based on the last menstrual period in the
remaining cases. Spontaneous PTD was defined as birth
after preterm labor or pre-labor rupture of the mem-
branes between 22+0 and 36+6 weeks. To distinguish be-
tween early and late spontaneous PTDs, we used the
following gestational time-windows: early (22+0-33+6)
and late (34+0-36+6) PTD.
Exposure
Amount of folate intake
The amount of folate intake was calculated from the
MoBa FFQ, a semi-quantitative questionnaire designed
to yield information regarding the dietary habits and in-
take of dietary supplements during the first 5 months of
pregnancy. The questionnaire data were read optically,
and the nutrient and energy intakes were calculated
using FoodCalc [31] and the Norwegian Food Compos-
ition Table [32]. For the calculation of nutrients in the
dietary supplements, an Access database containing the
nutrient values of more than 1,000 dietary supplements
was created and continuously updated using Microsoft
Office 2003 software. Dietary supplements commonlysold in Norway were registered based on information
provided by the respective manufacturer, whereas nutri-
tional information concerning dietary supplements bought
from the Internet or abroad were obtained from the man-
ufacturer’s or supplier’s homepage. A data program con-
nected to the Access database read all food supplements
recorded by the MoBa participants. The process of extract-
ing dietary and supplement data is described in detail else-
where [33,34].
Dietary folate was defined as 60% of the reported fol-
ate intake from foods, as only approximately 60% may
be biologically accessible in comparison to that from
the synthetic folic acid in supplements [1,3]. The total
folate intake was thus calculated as supplemental folic
acid +0.6 × folate intake from foods.
The daily folate intake was also categorized into 4
groups: <170 μg/d (corresponding to the earlier WHO rec-
ommendation for all women to prevent anemia [10,35]),
170–500 μg/d (corresponding to the current Nordic Nutri-
tion Recommendations for pregnant women for the pre-
vention of NTDs [2]), 500–1000 μg/d (corresponding to
the tolerable upper limit for folic acid [2]) and >1000 μg/d.
Timing of folic acid supplementation
The women reported their folic acid supplement use
from 26 weeks before conception until gestational week
24 in 4-week intervals, including the frequency of
supplementation. A woman was defined as a folic acid
supplement user if she reported any use of folic acid –
containing supplements for more than once a week in a
registered 4-week period. Folic acid may be consumed
either in the form of a folic acid supplement alone or as
part of multivitamins. The most commonly used folic
acid supplements for pregnant women in Norway con-
tain 400 μg of folic acid, while the most commonly used
multivitamin supplements contain 200 μg of folic acid.
For this study, the start of folic acid supplementation
was categorized as start during 26–9 weeks before con-
ception, start during 8–0 weeks before conception, and
no preconceptional folic acid supplementation.
Covariates
Covariates were chosen a priori based on the available
literature. Information regarding the maternal age at de-
livery as well as the child’s sex is available from the
MBRN. Parity was based on data from both the MoBa
and MBRN and based on the number of previous preg-
nancies of ≥22+0 weeks’ duration. Marital status was
defined as either married/cohabitant or not. The self-
reported pre-pregnancy heights and weights were used
to calculate the pre-pregnancy body mass index (BMI)
and were grouped according to the WHO classification
as underweight (<18.5 kg/m2), normal (18.5-24.9 kg/m2),
overweight (25.0-29.9 kg/m2) and obese (≥30.0 kg/m2).
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and ≥17 y. The history of previous PTD before 37+0 weeks
of gestation, and the history of spontaneous abortion, as
registered in the MBRN, were taken into account as di-
chotomous variables in regression models. Women re-
ported smoking habits during pregnancy in Q1 and
were categorized as non-smokers, occasional or daily
smokers. The alcohol intake from different sources was
self-reported in the FFQ (glasses/d, week or month) and
calculated as g/d. The household income was classified as
both the participant and her partner having <300,000
Norwegian Kroner (NOK)/y, as either the participant or
her partner having ≥300,000 NOK/y or as the participant
and her partner both having ≥300,000 NOK/y. Vitamin A
supplementation was registered and categorized in the
same manner as described for folic acid. These variables
were used as a proxy for multivitamin supplementation, as
there are no products on the Norwegian market contain-
ing vitamin A alone, and vitamin A is part of all common
multivitamin preparations. In MoBa more than 99% of the
participants are of Caucasian ethnicity; hence, ethnicity
was not a relevant confounder.
Statistical methods
All statistical analyses were performed using IBM SPSS
Statistics 22 and R 2.13.1 software. Total dietary folate
intake from foods and supplements (median (IQR)) in
relation to the maternal characteristics was studied with
the Kruskal-Wallis test. The start of folic acid supple-
mentation in relation to the maternal characteristics was
studied with Pearson’s chi-squared test. The association
of total dietary folate intake and spontaneous PTD was
estimated as a hazard ratio (HR) with a 95% confidence
interval (CI) by using Cox regression both in an un-
adjusted model and adjusted for the above-mentioned
covariates. In these models, the event was defined as a
spontaneous PTD; all iatrogenic deliveries and deliver-
ies after the preterm (≥37+0 weeks) or early preterm
(≥34+0 weeks) period were censored. The proportional
hazards assumption was investigated by testing and
inspecting scaled Schoenfeld residuals using R function
cox.zph [36]. Statistical significance was assumed for 2-
sided p-values of <0.05.
Results
Folate intake and folic acid supplementation in the study
population
The median total dietary folate intake during the first
five months of pregnancy and start of folic acid supple-
mentation according to maternal characteristics are pre-
sented in Table 1. Dietary folate intake was highest in
women aged 25–29 years, in women who did not smoke,
had low or normal BMI (18.5-24.9 kg/m2), who were
having their first child, were married/cohabitant, whohad higher education levels and family incomes. Women
having experienced PTD had significantly lower total fol-
ate intakes. While women with a history of spontaneous
abortion had more often started folic acid supplementa-
tion early, no comparable pattern in women with a his-
tory of PTD was found (Table 1).
Figure 1 illustrates the pattern of folic acid supplementa-
tion in the study population compared to vitamin A supple-
mentation (as a proxy for multivitamin consumption) over
the course of pregnancy. 85% of all women in the study re-
ported folic acid supplementation at some point before
and/or during pregnancy (Figure 1). While 44% initiated
folic acid supplementation prior to conception, nearly 77%
used supplements containing folic acid in the first trimester
with decreasing use towards the end of pregnancy. At the
same time, vitamin A supplementation was much more
stable over the whole length of the pregnancy. The amount
of folic acid supplementation varied considerably, with only
2 women consuming folic acid amounts of >5000 μg/d, 610
consuming >1000 μg/d (1%), 6,834 consuming >500 μg/d
(10%), 10,681 consuming >400 μg/d (16%), 27,183 consum-
ing >200 μg/d (41%) and 34,234 consuming >100 μg/d
(52%). Among supplement users, the median daily folic acid
supplementation was 400 μg/d (interquartile range IQR
200–429). As presented in Table 2, folic acid from supple-
ments was the main folate source in supplement users,
while the main source was dietary folate in the whole popu-
lation. There is no mandatory folate fortification of foods in
Norway, and only 3% (n = 1,946, not adjusted for bioavail-
ability) of the study population reached the Nordic Nutri-
tion Recommendation of 500 μg/d with their dietary folate
intake. Of the study participants, 44% (n = 28,959, not ad-
justed for bioavailability) achieved the recommended levels
with their total folate intake.
Folate intake from different sources and risk for
spontaneous PTD
The median gestational age in this study population was
281 days (IQR 274–287), with 2,906 (4%) cases of PTD
and 1,755 cases of spontaneous PTD (2.7%). Of these,
334 babies were delivered before 34+0 weeks of gestation
(0.5%). Thus the overall PTD rate in our study popula-
tion is approximately half of the PTD rate in the general
Norwegian population as we excluded risk-pregnancies
due to maternal disease as well as multiple gestations
and intrauterine death.
There was no significant association between the
amount of folate intake from the diet or supplements
with the risk of spontaneous PTD (Table 3). As 95% CIs
were very narrow, we performed the same analysis in
deciles of total folate intake as well with a categorized
variable according to deciles of total folate intake with
no change of results (data not shown). Likewise, no as-
sociation was found when the total folate intake was
Table 1 Folate variables and maternal characteristics
Total folate intake (μg/d) Initiation of preconceptional folic acid supplementation, n (%)
n (%) Median (IQR) p1 >8 w 0-8 w No p2
Total 66014 (100) 313 (167–558) 16023 (24) 12877 (20) 37114 (56)
<25 7561 (12) 258 (154–528) 849 (11) 942 (13) 5770 (76)
Maternal age in years 25-29 22672 (34) 324 (170–562) <0.0001 5121 (23) 4821 (21) 12730 (56) <0.0001
30-34 27993 (42) 319 (168–562) 7726 (28) 5894 (21) 14373 (51)
>34 7788 (12) 315 (170–562) 2327 (30) 1220 (16) 4241 (55)
Pre-pregnancy BMI in kg/m2 <18.5 19\31 (3) 343 (179–575) 432 (22) 351 (18) 1148 (60)
18.5-24.9 42611 (65) 328 (173–566) <0.0001 10773 (25) 8637 (20) 23201 (54) <0.0001
25-30 13839 (21) 289 (160–548) 3228 (23) 2651 (19) 7960 (58)
≥30 5970 (9) 268 (151–533) 1305 (22) 953 (16) 3712 (62)
Missing 1663 (3) 250 (156–517) 285 (17) 285 (17) 1093 (66)
0 34825 (53) 355 (180–580) 9324 (27) 6480 (19) 19021 (55)
1 20028 (30) 281 (159–545) <0.0001 4528 (23) 4531 (23) 10969 (55) <0.0001
Parity 2 9005 (14) 245 (156–517) 1787 (20) 1570 (17) 5648 (63)
3+ 2101 (3) 224 (149–451) 370 (18) 285 (14) 1446 (69)
Missing 55 (0.1) 353 (166–566) 14 (26) 11 (20) 30 (55)
Marita status Yes 63518 (96) 315 (168–559) <0.0001 15714 (25) 12661 (20) 35143 (55) <0.0001
No 2496 (4) 266 (158–531) 309 (12) 216 (9) 1971 (79)
Maternal education in years <13 20198 (31) 244 (150–515) 3263 (16) 2886 (14) 14049 (70)
13 - 16 27606 (42) 338 (172–567) <0.0001 7118 (26) 5849 (21) 14639 (53) <0.0001
>16 16838 (26) 374 (187–581) 5340 (32) 3916 (23) 7582 (45)
Missing 1372 (2) 283 (161–550) 302 (22) 226 (17) 844 (62)
History of preterm
delivery
No 63698 (97) 314 (168–559) <0.0001 15510 (24) 12411 (20) 35777 (56) 0.047
Yes 2205 (3) 276 (158–539) 487 (22) 435 (20) 1283 (58)
Missing 111 (0.2) 297 (175–560) 26 (23) 31 (28) 54 (49)
History of abortion No 45164 (68) 315 (168–559) 0.15 10262 (23) 8930 (20) 25972 (58) <0.0001
Yes 12418 (19) 308 (166–558) 3932 (32) 2296 (19) 6190 (50)
Missing 8432 (13) 308 (165–557) 1829 (22) 1651 (20) 4952 (59)
Never 60452 (92) 322 (170–563) 15339 (25) 12271 (20) 32842 (54)
Smoking habits Occasionally 1741 (3) 261 (158–511) <0.0001 243 (14) 226 (13) 1272 (73) <0.0001
Daily 3449 (5) 217 (141–485) 378 (11) 316 (9) 2755 (80)
Missing 372 (0.6) 236 (148–500) 63 (17) 64 (17) 245 (66)
Alcohol consumption
in units/week
No alcohol 58659 (89) 314 (167–559) 14448 (25) 11528 (20) 32683 (56)
<0.5 6155 (9) 311 (170–556) 0.21 1326 (22) 1164 (19) 3665 (60) <0.0001
≥0.5 1200 (2) 286 (167–531) 249 (21) 185 (15) 766 (64)
Partners with
income of >300,000
0 18364 (28) 279 (161–540) <0.0001 3176 (17) 2904 (16) 12284 (67)
1 27212 (41) 309 (166–557) 6460 (24) 5451 (20) 15301 (56) <0.0001
2 18608 (28) 360 (178–579) 6130 (33) 4247 (23) 8231 (44)
NOK/year Missing 1830 (3) 264 (158–533) 257 (14) 275 (15) 1298 (71)
Baby’s sex Male 33791 (51) 309 (166–558) 0.07 8190 (24) 6525 (19) 19076 (57) 0.4
Female 32223 (49) 316 (169–559) 7833 (24) 6352 (20) 18038 (56)
Tertiles of energy intake in MJ 1 22005 (33) 272 (127–525) 5577 (25) 4338 (20) 12090 (55)
2 22005 (33) 317 (166–561) <0.0001 5511 (25) 4485 (20) 12009 (55) <0.0001
3 22004 (33) 344 (211–600) 4935 (22) 4054 (18) 13015 (59)
Amount of total daily folate intake (FFQ data) and initiation of preconceptional folic acid supplementation (Q1 data) according to maternal characteristics, from
66,014 participants in the Norwegian Mother and Child Cohort Study (2002 – 2009).
1p-value, estimated with Kruskal-Wallis test.
2p-value, estimated with Pearson’s chi-squared test.
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mendation for women (>170 μg/d), the current Nordic
Nutrition Recommendations for pregnant women
(>500 μg/d) and the tolerable upper limit (for folic acid
supplementation: <1000 μg/d) (Additional file 1: Table
S1). Cox regression for the sub-groups of early and late
spontaneous PTD did not reveal any significant associ-
ations between the folate intake and pregnancy out-
come (not shown). Testing the proportional hazards
assumptions revealed a slight misfit for the parity vari-
able. Therefore all analyses were also run with stratified
Cox regression using parity as strata. The changes from
the unstratified analyses were however marginal and
did not change any pattern or results.
Initiation of folic acid supplementation and risk for
spontaneous PTD
The initiation of folic acid supplementation more than
8 weeks preconception was associated with increased
risk of spontaneous PTD overall also after adjusting for
potential confounders (Table 4 and Additional file 2:
Figure S1a; hazard ratio HR 1.19; confidence interval CI
1.05-1.34). The initiation of supplementation more than
8 weeks before conception was significantly associated
with early (<34+0 weeks) but not late spontaneous PTD
(Additional file 3: Figure S1b). After stratification for the
total dietary folate intake from foods, the initiation of
folic acid supplementation more than 8 weeks before
conception was significantly associated with an increased
risk of spontaneous PTD for those women with low diet-
ary folate intakes (adjusted HR 1.18; 95% CI 1.05-1.32).
The same association was found in the subgroup of early
(adjusted HR 1.60; 95% CI 1.24-2.10) but not late spon-
taneous PTD (Additional file 4: Table S2).Figure 1 Prevalence of folic acid and vitamin A supplementation
during pregnancy. Prevalence of folic acid and vitamin A
supplementation during pregnancy (Q1 and Q3 data) in women with
spontaneous non-preterm (37+0-42+6 weeks, n = 51,141) or preterm
delivery (22+0-36+6 weeks, n = 1,755) among 66,014 participants in the
Norwegian Mother and Child Cohort Study (2002 – 2009).A history of earlier adverse pregnancy outcome could
be a motive for the early initiation of folic acid supple-
mentation in subsequent pregnancies. However, the ana-
lysis of the subgroup of women being pregnant the first
time (n = 25,281, 38%) showed the same overall results
for the early initiation of folic acid supplementation (n =
815 cases of spontaneous PTD, adjusted HR 1.30; CI
1.10-1.53).
The early initiation of folic acid supplementation could
characterize women that planned a pregnancy but did
not become pregnant during the first months, thus in-
cluding a subgroup of sub-fertile women [37]. In MoBa,
the women were asked to report the number of months
with regular intercourse without contraception before
becoming pregnant, and these data were classified as fol-
lows: <1 month (n = 13,128, 20%), 1–2 months (n =
15,142, 23%) and >2 months (n = 22,702, 34%). Stratifi-
cation for this variable still showed increased HRs for
the early initiation of folic acid supplementation in the
subgroup that became pregnant within the first month
(adjusted HR 1.58; CI 1.17-2.12), the HRs for the small
subgroup with early PTD (n = 68) was not significant
(adjusted HR 1.78; CI 0.98-3.23).
Timing of folic acid supplementation and risk for
spontaneous PTD
The time of folic acid supplementation was represented by
four variables corresponding to the following periods: 26–
9 weeks before conception, 0–8 weeks before conception,
first trimester and second trimester. If the Cox regression
included all of the confounders and the outcome of spon-
taneous PTD was analyzed, the prediction of the model
improved after introducing all four folic acid supplementa-
tion variables (p = 0.006). Folic acid supplement use more
than 8 weeks preconception was associated with an in-
creased HR for spontaneous PTD, even after adjusting for
the supplementation at all other time points (Table 5).
Discussion
In this large prospective national birth cohort, we did
not find any statistically significant association of the
amount of folate intake from the diet or supplements
with spontaneous PTD. Folic acid supplementation start-
ing more than 8 weeks before conception was associated
with an increased HR for spontaneous PTD.
When interpreting the results, the selection of the study
population has to be kept in mind: risk-pregnancies due to
maternal disease and multiple gestations have been ex-
cluded from the analysis so that we do not know if there is
any association of the amount of folate intake from diet or
supplements with spontaneous PTD in the excluded high
risk pregnancies.
Our results, demonstrating no significant protective
effect of the maternal folate intake or folic acid
Table 2 Folate intake from diet and supplements
All Spontaneous delivery 37+0- 42+6 Spontaneous PTD 22+0-36+6
Folate (μg/d) Median IQR Median IQR Median IQR
All women n = 66014 n = 51141 n = 1755
Diet 157 (126–196) 157 (126–196) 157 (126–196)
Supplements 143 (0–400) 143 (0–400) 171 (0–400)
Total intake 313 (167–558) 312 (167–558) 322 (167–568)
Supplement users n = 39600 n = 30684 n = 1056
Diet 158 (127–197) 158 (127–197) 159 (128–198)
Supplements 400 (200–429) 400 (200–429) 400 (200–457)
Total intake 530 (355–636) 530 (355–634) 541 (369–651)
Folic acid supplementation, dietary and total folate intake during the first half of pregnancy (FFQ data) for all 66,014 participants, as well as in folic acid
supplement users (n = 39,600), from the Norwegian Mother and Child Cohort Study (2002–2009).
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number of earlier observational studies [38-43] and RCTs
[6,44,45]. A reanalysis of a previous Cochrane review, and
one of the largest RCTs, a recent meta-analysis of all RCTs
published to date as well as the most recent Cochrane re-
view based on 3 available trials, showed no association of
the maternal folate status with the gestational length or
the risk of PTD [23-25]. Extensive supplementation with
multivitamins with a major folic acid component was asso-
ciated with an increased risk of PTD in a study by Alwan
et al. [38]. When analyzing data from the US National
Birth Defects Study, Shaw et al. found a lower risk of PTD
for women starting supplementation during pregnancy as
compared to preconceptional supplementation start [43].
However, results are conflicting as summarized in the
review by Mantovani et al. [27]. A protective effect of
folic acid supplementation was supported by a modest
reduction in the PTD rate after the introduction of folate
fortification of foods [9]. Some recent observational studies
have found that folic acid supplementation reduces the
risk of PTD [20-22]. In some cases, this association was
found for preconceptional folic acid supplementation forTable 3 Folate intake from different sources and risk of
spontaneous preterm delivery (PTD)
Unadjusted Adjusted2
Folate (μg/d) HR1 (95% CI) p HR1 (95% CI) p
Diet 1.00 (0.61; 1.65) 0.61 1.00 (0.61; 1.65) 0.54
Supplements 1.00 (1.00; 1.00) 0.25 1.00 (1.00; 1.00) 0.53
Total intake 1.00 (1.00; 1.00) 0.22 1.00 (1.00; 1.00) 0.46
Amount of folic acid supplementation, dietary and total folate intake (FFQ
data) and hazard ratios for spontaneous PTD (22+0-36+6 weeks, n = 1,755). Cox
regression for 66,014 participants in the Norwegian Mother and Child Cohort
Study (2002–2009). Iatrogenic deliveries have been censored in the
regression model.
1HR per 500 μg extra folate/d.
2Cox regression, adjusted for maternal age, prepregnancy BMI, parity, history
of PTD and spontaneous abortion, child’s sex, smoking habits and alcohol
consumption during pregnancy, maternal education, marital status, household
income, energy intake. Mutual adjustment for dietary and supplemental
folate intake.1 year or longer [21] or third-trimester folic acid supple-
mentation [22], raising questions about extended supple-
mentation schemes compared to the NTD prevention
scheme. Folic acid supplementation more than a 1 year be-
fore becoming pregnant is not registered in MoBa, but
data for the earliest interval (26–9 weeks before concep-
tion) suggest an adverse effect of longtime folic acid sup-
plementation on the risk of spontaneous PTD. Though
third trimester folic acid supplementation is registered in
MoBa, we chose to not include third trimester supplemen-
tation as the early PTDs already have occurred at different
time points during this period, so that we were not able to
retrace the findings by Czeizel et al. [22].
One possible explanation for these conflicting results
could be the dosage of folic acid. While most of the
studies finding an association with gestational length or
PTD were based on high doses of folic acid (≥5000 μg/d
[20,22,46], ≥2500 μg/d [22,47] and ≥500 μg/d [48-50]),
only 2 women in our study population consumed as
much as 5000 μg/d of supplemental folic acid, while only
10% consumed >500 μg/d and 16% consumed >400 μg/
d. However, the Hungarian RCT, one of the biggest per-
formed so far, did not find any effect of a high dosage of
800 μg/d of periconceptional folic acid supplementation
on PTD [6]. Unfortunately, the folic acid dosage was not
indicated in all of the studies [21,37].
The assessment of folate intake from supplementation
alone or when studying populations with different dietary
folate intakes are additional factors compromising com-
parability between studies. While recent US studies are
performed against the background of mandatory folate for-
tification of food [21,43], other studies have examined sup-
plementation effects in folate-deficient populations [46].
Few studies have assessed the effects of both dietary folate
and folic acid supplementation separately [43] or com-
bined [20,49,51], and adjustments for bioavailability are
rare. In this Norwegian study population, only 3% of
the participants reached the Nordic Nutrition Recom-
mendation of 500 μg/d with their dietary folate intake,
Table 4 Initiation of preconceptional folic acid supplementation and risk of spontaneous preterm delivery (sPTD)
sPTD Initiation of folic acid supplementation Unadjusted Adjusted1 Adjusted2
n HR (CI) p HR (CI) p HR (CI) p
All No 964 1 1 1
0-8 w preconception 313 0.93 (0.82; 1.06) 0.28 0.99 (0.87; 1.13) 0.89 1.01 (0.88; 1.16) 0.88
>8 w preconception 478 1.15 (1.03; 1.29) 0.01 1.18 (1.05; 1.32) 0.005 1.20 (1.06; 1.36) 0.004
Early No 169 1 1 1
0-8 w preconception 57 0.97 (0.72; 1.31) 0.84 1.07 (0.79; 1.45) 0.67 1.04 (0.76; 1.43) 0.81
>8 w preconception 108 1.48 (1.16; 1.89) 0.001 1.60 (1.24; 2.06) <0.001 1.55 (1.18; 2.05) 0.002
Late No 795 1 1 1
0-8 w preconception 256 0.92 (0.80; 1.06) 0.23 0.97 (0.84; 1.11) 0.63 0.99 (0.86; 1.15) 0.93
>8 w preconception 370 1.08 (0.96; 1.22) 0.22 1.09 (0.96; 1.24) 0.19 1.12 (0.98; 1.29) 0.11
Initiation of preconceptional folic acid supplementation (Q1 data) and hazard ratios (HR) for spontaneous PTD (n = 1,755 for 22+0-36+6 weeks, n = 334 for early
(22+0-33+6 weeks), n = 1,421 for late (34+0-36+6 weeks)). Cox regression for 66,014 participants in the Norwegian Mother and Child Cohort Study (2002 – 2009).
Iatrogenic deliveries have been censored in the regression model.
1Cox regression, adjusted for maternal age, prepregnancy BMI, parity, history of PTD and spontaneous abortion, child’s sex, smoking habits and alcohol
consumption during pregnancy, maternal education, marital status, household income, energy intake and dietary folate intake.
2Adjustment as above as well as for first-trimester folic acid supplementation and preconceptional and first-trimester vitamin A supplementation.
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level with their dietary folate and supplemental folic
acid intake. After stratification for dietary folate intake,
the early initiation of folic acid supplementation was
significantly associated with spontaneous PTD in the
subgroup of women with low but not high dietary folate
intakes. There were no significant associations between
high total folate intakes and PTD risk in the MoBa
study population.
In observational studies, confounding is always an issue
when assessing the association of a single environmental
factor with a complex outcome like PTD. For example, itTable 5 Timing of folic acid supplementation and risk of spon
Time of folic acid supplementation sPTD Unad
n HR
All >8 w preconception 478 1.17
0-8 w preconception 648 1.01
1st trimester 1326 0.94
2nd trimester 869 1.10
Early >8 w preconception 108 1.49
0-8 w preconception 133 1.15
1st trimester 262 1.11
2nd trimester 173 1.21
Late >8 w preconception 370 1.10
0-8 w preconception 515 0.98
1st trimester 1064 0.91
2nd trimester 696 1.08
Folic acid supplementation at different times (Q1 and Q3 data) and hazard ratios (H
(22+0-33+6 weeks), n = 1,421 for late (34+0-36+6 weeks)) as compared to no intake a
Norwegian Mother and Child Cohort Study (2002 – 2009). Iatrogenic deliveries have
1Cox regression, adjusted for maternal age, prepregnancy BMI, parity, history of PTD
consumption during pregnancy, maternal education, marital status, household inco
supplementation at other time points.is well established that women with high levels of educa-
tion, privileged socioeconomic status and healthier overall
diets are more likely to use supplements during pregnancy
[52-54] and less likely to experience PTD than women
without these characteristics. Some observational studies
failed to adjust for these confounders, and the effect at-
tributed to folic acid supplementation might in fact be
confounded by overall health and lifestyle behaviors. While
the strength of the significance was moderate, the asso-
ciation with the early onset of folic acid supplementa-
tion in the current study remained significant even
after adjustment for maternal characteristics such astaneous preterm delivery (PTD)
justed Adjusted1
(CI) p HR (CI) p
(1.06; 1.30) 0.003 1.17 (1.04; 1.32) 0.01
(0.92; 1.12) 0.80 1.01 (0.90; 1.13) 0.84
(0.84; 1.05) 0.26 0.89 (0.79; 1.00) 0.05
(1.00; 1.21) 0.04 1.08 (0.98; 1.19) 0.11
(1.19; 1.88) 0.001 1.51 (1.16; 1.97) 0.002
(0.92; 1.43) 0.23 1.03 (0.80; 1.34) 0.81
(0.85; 1.44) 0.45 0.99 (0.74; 1.32) 0.95
(0.97; 1.49) 0.09 1.12 (0.89; 1.39) 0.34
(0.98; 1.24) 0.10 1.10 (0.97; 1.26) 0.15
(0.88; 1.09) 0.69 1.00 (0.88; 1.13) 0.94
(0.81; 1.03) 0.13 0.87 (0.76; 1.00) 0.04
(0.98; 1.20) 0.13 1.08 (0.97; 1.20) 0.17
R) for spontaneous PTD (n = 1.755 for 22+0-36+6 weeks, n = 334 for early
t that time of pregnancy. Cox regression for 66,014 participants in the
been censored in the regression model.
and spontaneous abortion, child’s sex, smoking habits and alcohol
me, energy intake and dietary folate intake. Mutual adjustment for folic acid
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stetric anamnesis.
Associations with the early start of supplementation
should be studied with particular caution. The early start
of folic acid supplementation might partially identify a
group of women with a history of adverse pregnancy out-
comes who want to optimize conditions for their current
pregnancy. As presented in Table 1, women who had pre-
viously experienced spontaneous abortions were more
likely to initiate folic acid supplementation early in their
subsequent pregnancies. However, the same association of
the early initiation of folic acid supplementation and spon-
taneous PTD was found in women being pregnant the first
time. Folic acid supplementation starting more than
8 weeks prior to conception might characterize women
who planned a pregnancy but did not become pregnant
during their first 2 cycles, thus constituting a subgroup of
women with suboptimal fertility [37]. The same associ-
ation of the early start of supplementation was found in
the group of women that became pregnant within the first
month. Women who choose to start early with folic acid
supplementation might be distinguished by some other
characteristic that could be the causal link to spontaneous
preterm delivery so that we cannot exclude confounding.
In addition to the amount of folic acid, the compos-
ition of supplements is another point of discussion. In
some countries like Greece and Norway, commonly used
supplements contain folic acid and/or iron only [20]. In
other countries, folic acid is mainly consumed in the
form of multivitamins, making it difficult to differentiate
the effects of multivitamin use and folic acid supplemen-
tation [21,37,43,50]. Vitamins other than folic acid might
explain the association between multivitamin use and
PTD. Catov et al. found that in the Danish birth cohort,
multivitamin use was associated with modestly decreased
PTD rates, while there was no association with folic acid
supplementation [39]. As seen from Figure 1, vitamin A
consumption (as a proxy for multivitamin supplementa-
tion) differed considerably from folic acid supplementa-
tion. However, the MoBa FFQ allowed us to calculate folic
acid separately from other supplements, and adjusting for
vitamin A consumption did not change the results for pre-
conceptional folic acid supplementation.
Apart from the amount, timing and composition of folate
exposure, differences in the definition of pregnancy out-
comes hinder comparability. Most studies defined PTD as
delivery at <37+0 weeks of gestation without indicating the
range of gestational age. This information might be import-
ant, especially if the risk of early PTD is found to be associ-
ated with folate status, as suggested by this study and that
of Bukowski et al. [21]. Although PTD is a heterogeneous
pregnancy outcome with distinct etiologies for different
subgroups [26], not all studies analyzed clearly defined sub-
groups such as spontaneous PTD [20,21,39,42,49,55].Strengths and weaknesses
With a sample size of 66,014 pregnancies, this was a well-
powered study for investigating the association of folate in-
take and spontaneous PTD. Due to the large study sample,
there were 1,755 cases defined as spontaneous PTD and
334 and 1,421 cases in the subgroups of early and late
spontaneous PTD, respectively. The estimation of the ges-
tational length by the second-trimester ultrasounds and
the definition of a clear PTD phenotype – spontaneous on-
set of delivery between 22+0 and 36+6 weeks of gestation -
distinguish this study.
The MoBa participation rate is 38.5%, and a demo-
graphic comparison with the MBRN in 2002 showed
that single women and women <25 y of age are under-
represented in MoBa. Regarding PTD (7.2% in MoBa
and 7.7% in MBRN), the differences are minor, and even
the sub-group composition is similar to the distribution
in the total population, with spontaneous PTD account-
ing for 42% of all PTD [15]. Although the low participa-
tion in MoBa influences prevalence estimates somewhat,
such non-representativeness does not appear to affect
exposure–outcome associations [56,57].
The assessment of folate from both the diet and sup-
plements is a major strength of this study. Although all
dietary assessment methods have limitations, the MoBa
FFQ has been extensively validated in a sub-population
of 119 MoBa participants using a 4-day weighed food
diary and biological markers in the blood and urine as
reference measures [58]. The dietary supplement use
was evaluated specifically. The total folate intake by the
FFQ showed good agreement with the folate intake de-
tailed by the food diary and was significantly reflected by
the serum folate concentrations [33]. In a subsample of
an earlier MoBa version (2934 singleton pregnancies),
Nilsen et al. did not find any significant associations of
dietary folate intake, folic acid supplementation or
plasma folate with PTD. This study also reported good
agreement between the folate intake (dietary and supple-
ments) by the MoBa FFQ and plasma folate concentra-
tion (r = 0.44, CI: 0.41-0.47) [40]. As the relevant
window of susceptibility for folate effects regarding preg-
nancy outcomes other than NTD is not yet known, the
assessment of folate intake at different time points is a
further strength of this study. The prospective design en-
sured that the women’s answers were not influenced by
their knowledge of pregnancy outcomes.
Conclusions
The overall amount of dietary folate and supplemental
folic acid intake (during the first half of pregnancy) in
66,014 singleton pregnancies from the Norwegian Mother
and Child Cohort Study was not associated with decreased
or increased risk of spontaneous PTD, at least not at
the relatively low intake levels of dietary folate (median
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262 μg/d) and supplemental folic acid (median 143 μg/d)
in this healthy study population.
The initiation of folic acid supplementation more than
8 weeks prior to conception was associated with an in-
creased risk for overall and early spontaneous PTD in
both the overall analyses and in the strata of women
with low dietary folate intake.
Even if MoBa allows adjustment for a variety of con-
founders, the presence of residual confounding cannot
be ruled out. Furthermore, our results require careful in-
vestigation regarding dosage and timing of folic acid
supplementation, such as in the form of an RCT, before
discussing a change of the current guidelines.
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